Increased serum interleukin-34 levels as a novel diagnostic and prognostic biomarker in patients with acute ischemic stroke

J Neuroimmunol. 2021 Sep 15:358:577652. doi: 10.1016/j.jneuroim.2021.577652. Epub 2021 Jun 30.

Abstract

Background: Recent data reveal that interleukin-34 (IL-34) can drive inflammatory response, thereby participating in the pathogenesis of inflammatory diseases. However, the potential effect of IL-34 in acute ischemic stroke (AIS) remains unknown. The purpose of this study was to explore whether the levels of serum IL-34 were correlated with clinical severity or prognosis in AIS patients.

Methods: In this prospective cohort study, serum IL-34 levels were detected in 150 healthy controls and 155 AIS patients. Univariate and multivariate logistic regression analysis were conducted to investigate the effect of IL-34 on the diagnosis and prognosis of AIS. ROC curve was utilized to evaluate predictive values for IL-34.

Results: Serum IL-34 levels at admission were significantly higher in AIS patients than those in the healthy controls. Univariate and multivariate logistics regression analysis showed that IL-34 was an independent predictor of occurrence and functional outcome of AIS. The ROC curve demonstrated that IL-34 had a good predictive effect on the diagnosis and prognosis of AIS.

Conclusions: IL-34 can be used as a novel and independent diagnostic and predicting prognostic biomarker in AIS.

Keywords: Acute ischemic stroke; Biomarker; Diagnosis; Interleukin-34; Prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Brain Ischemia / blood*
  • Brain Ischemia / diagnosis*
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukins / blood*
  • Ischemic Stroke / blood*
  • Ischemic Stroke / diagnosis*
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies

Substances

  • Biomarkers
  • IL34 protein, human
  • Interleukins